GlassScriptPhysician profile
Jodie Calain
NPI 1912135492
$1,046.38
in general payments reported to CMS, 2019-2025
23 companies · $22.67 in 2025
The $22.67 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $270 · 2020: $64.37 · 2021: $14.69 · 2022: $296 · 2023: $379 · 2025: $22.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $401.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $401.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $126.50 | 2022 | |
| Relievant Medsystems, INC. | $124.10 | 2023 | Intracept |
| Boston Scientific Corporation | $99.94 | 2019 | |
| Pfizer INC. | $92.05 | 2019-2025 | |
| Lilly USA, LLC | $89.83 | 2019-2023 | Mounjaro, Jardiance |
| Abbvie INC. | $59.28 | 2022-2023 | Ubrelvy |
| Janssen Pharmaceuticals, INC | $56.86 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $38.80 | 2019-2023 | Flumist Quadrivalent |
| Amgen INC. | $37.15 | 2019-2023 | Repatha, Otezla |
| Amarin Pharma, INC. | $33.41 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.40 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $31.18 | 2019 | |
| Abbott Laboratories | $30.71 | 2022 | |
| Novo Nordisk INC | $28.88 | 2021-2023 | Ozempic, Rybelsus |
| Inspire Medical Systems, INC. | $27.42 | 2023 | Inspire |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $20.27 | 2022 | |
| Zyla Life Sciences, INC. | $20.07 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.84 | 2023 | Jardiance |
| Glaxosmithkline, LLC. | $18.56 | 2023 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $15.93 | 2019 | |
| Idorsia Pharmaceuticals US INC | $15.72 | 2023 | Quviviq |
| Global Blood Therapeutics, INC. | $15.34 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $13.14 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jodie Calain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.